Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects With Chronic Hepatitis C Infection
Conditions
Interventions
ACH-0137171
Locations
9
United States
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
La Jolla, California, United States
Clinical Trial Site
San Francisco, California, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
Dallas, Texas, United States
Start Date
November 30, 2006
Completion Date
March 31, 2007
Last Updated
September 15, 2022
NCT06928259
NCT05992077
NCT05534633
NCT07412977
NCT07241962
NCT04134767
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions